Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy

by Ting Huang, Huiqiang Wang, Nanhai G Chen, Alexa Frentzen, Boris Minev, Aladar A Szalay
Published 2015-01-01

Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis

by Desislava Tsoneva, Boris Minev, Alexa Frentzen, Qian Zhang, Anja K. Wege, Aladar A. Szalay
Published 2017-06-01

Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy

by Marion Adelfinger, Simon Bessler, Alexa Frentzen, Alexander Cecil, Johanna Langbein-Laugwitz, Ivaylo Gentschev, Aladar A. Szalay
Published 2015-07-01

Drug-Encoded Biomarkers for Monitoring Biological Therapies.

by Desislava Tsoneva, Jochen Stritzker, Kristina Bedenk, Qian Zhang, Alexa Frentzen, Joseph Cappello, Utz Fischer, Aladar A Szalay
Published 2015-01-01

Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.

by Sandeep S Patil, Ivaylo Gentschev, Marion Adelfinger, Ulrike Donat, Michael Hess, Stephanie Weibel, Ingo Nolte, Alexa Frentzen, Aladar A Szalay
Published 2012-01-01

Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.

by Marion Adelfinger, Ivaylo Gentschev, Julio Grimm de Guibert, Stephanie Weibel, Johanna Langbein-Laugwitz, Barbara Härtl, Hugo Murua Escobar, Ingo Nolte, Nanhai G Chen, Richard J Aguilar, Yong A Yu, Qian Zhang, Alexa Frentzen, Aladar A Szalay
Published 2014-01-01